Elevated serum antimelanocyte antibody level in cerebriform intradermal nevus with vitiligo

Journal of Dermatology

Volumn 31, Issue 7, 2004, Pages 540-545

  Lee, Chih Hung ^a   Yu, Hsin Su ^b,c  

^a KAOHSIUNG MEDICAL UNIVERSITY   (Taiwan)

^b NATIONAL TAIWAN UNIVERSITY   (Taiwan)

^c NATIONAL TAIWAN UNIVERSITY   (Taiwan)

Author keywords

Antimelanocyte antibody; Cerebrifom intradermal nevus; Vitiligo

Indexed keywords

ANTIBODY; DOPA; MELANIN; MELANOCYTE ANTIBODY; PIGMENT; UNCLASSIFIED DRUG;

ADULT; ALOPECIA; ANTIBODY TITER; ARTICLE; CASE REPORT; CELL DIFFERENTIATION; CEREBRIFORM INTRADERMAL NEVUS; CONTROLLED STUDY; DISEASE ASSOCIATION; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; HUMAN TISSUE; HYPOPIGMENTATION; MALE; MELANOCYTE; MICROSCOPY; NEVUS; SKIN BIOPSY; VITILIGO;

EID: 3843057789     PISSN: 03852407     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1346-8138.2004.tb00551.x     Document Type: Article

References (28)

1. Orkin M, Frichot BC, Zelickson AS: Cerebriform intradermal nevus, a cause of cutis vertices gyrata, Arch Dermatol, 110: 575-582, 1974.
2. Polan S, Butterworth T: Cutis vertices gyrata: Review with report of seven new cases, Am J Ment Defic, 57: 613-631, 1953.
3. Goldstone S, Samitz MH, Carter DM: Giant cerebriform nevus of the scalp with malignant melanoma and metastasis, Arch Dermatol, 95: 137, 1967.
4. Gross PR, Carter DM: Malignant melanoma arising in a giant cerebriform nevus, Arch Dermatol, 96: 536-539, 1967.
5. Conley JJ: Malignant tumors of the scalp: An analysis of 58 cases of melanoma of the scalp, Plast Reconstr Surg, 33: 163-171, 1964.
6. Kopf AW, Bart RS: A congenital pigmented nevus associated with leukoderma, J Dermatol Surg Oncol, 7: 547, 1981.
7. Ridley CM: Giant halo nevus with spontaneous resolution, Trans St Johns Hosp Dermatol Soc, 60: 54, 1974.
8. King LA, King DT: Halo congenital nevus without histological inflammation, Arch Dermatol, 114: 1242, 1978.
9. Garcia RL, Gano SE: Halo congenital nevus, Cutis, 23: 338, 1979.
10. Langer K, Konrad K: Congenital melanocytic nevi with halo phenomenon: Report of two cases and a review of the literature, J Dermatol Surg Oncol, 16:377-380, 1990.
11. Zack LD, Stegmeier O, Solomon LM: Pigmentary regression in a giant nevocellular nevus: A case report and a review of the subject, Pediatr Dermatol, 5: 178-183, 1988.
12. Roenigk HH: Microtoxicity and serum-blocking factors in malignant melanoma and halo nevus, Arch Dermatol, 111: 720, 1975.
13. Hashimoto I, Urano Y, Nakanishi H, Oura H, Kato S, Arase S: Cerebriform intradermal nevus: A case of scalp expansion on the galea, J Dermatol, 26: 258-263, 1999.
14. Berman B, Shaieb AM, France DS, Altchek DD: Halo giant congenital melancytic nevus: In vitro immunologic studies, J Am Acad Dermatol, 19: 954-960, 1988.
15. Norris DA, Kissinger RM, Naughton GM, Bystryn JC: Evidence for immunologic mechanisms in human vitiligo: Patients' sera induce damage to human melanocytes in vitro by complement-mediated damage and antibody-dependent cellular cytotoxicity, J Invest Dermatol, 90: 783-789, 1988.
16. Yu HS, Kao CH, Yu CL: Coexistence and relationship of antikeratinocyte and antimelanocyte antibodies in patients with non-segmental-type vitiligo, J Invest Dermatol, 100: 828, 1993.
17. Yamakage A, Yamazaki S: Cerebrifom intradermal nevus, Int J Dermatol, 34: 634, 1995.
18. Jeanfils S, Tennustedt D, Lachapelle JM: Cerebriform intradermal nevus, Dermatol, 186: 294-297, 1993.
19. Tokura Y, Yamanaka K, Wakita H, et al: Halo congential nevus undergoing spontaneous regression. Involvement of T-cell immunity in involution and presence of circulating anti-nevus cell IgM antibodies, Arch Dermatol, 130: 1036-1041, 1994.
20. Naughton GK, Eisinger M, Bystryn JC: Detection of antibodies to melanocytes in vitiligo by specific immunoprecipitation, J Invest Dermatol, 81: 540-542, 1983.
21. Ongenae K, Van Geel N, Naeyaert JM: Evidence for an autoimmune pathogenesis of vitiligo, Pigment Cell Res, 16: 90-100, 2003.
22. Harning R, Cui J, Bystryn JC: Relation between the incidence and level of pigment cell antibodies and disease activity in vitiligo, J Invest Dermatol, 97: 1078-1080, 1991.
23. Fishman P, Azizi E, Shoenfeld Y, et al: Vitiligo autoantibodies are effective against melanoma, Cancer, 72: 2365-2369, 1993.
24. Gilhar A, Zelickson B, Ulman Y, Etzioni A: In vivo destruction of melanocytes by the IgG fraction of serum from patients with vitiligo, J Invest Dermatol, 105: 683-686, 1995.
25. Yi YL, Yu CH, Yu HS: IgG anti-melanocyte antibodies purified from patients with active vitiligo induce HLA-DR and intercellular adhesion molecule-1 expression and an increase in interleukin-8 release by melanocytes, J Invest Dermatol, 115:969-973, 2000.
26. Cui J, Arita Y, Bystryn JC: Cytolytic antibodies to melanocytes in vitiligo, J Invest Dermatol, 100: 812-815, 1993.
27. Bittencourt FV, Marghoob AA, Kopt AW, Koenig KL, Bart RS: Large congenital melanocytic nevi and the risk for development of malignant melanoma and neurocutaneous melanocytosis, Pediatrics, 106: 736-741, 2000.
28. Bystryn JC, Rigel D, Friedman RJ, Kopf A: Prognostic significance of hypopigmentation in malignant melanoma, Arch Dermatol, 123: 1053-1055, 1987.